Notice of Results

RNS Number : 1060G

Hikma Pharmaceuticals Plc

27 February 2018

 

Notice of Results

LONDON, UK, 27 February 2018 - Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) will announce its preliminary financial results for the year ended 31 December 2017 on Wednesday 14 March 2018.

A presentation and webcast for analysts will be held at 9.30am GMT at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 9.15am.

To join via conference call please dial:

UK Toll Free Number: 0808 109 0700

US Toll Free Number: 1 866 966 5335

Standard International Access: [phone]

Password: Hikma

The results presentation and a webcast recording of the event will be available on the Company's website at www.hikma.com or http://webcast.openbriefing.com/hikma_full_results_2018/ 

Playback facility:

A playback of the conference call will be available up to 7 days after the presentation.

UK & International Number: [phone]

Replay PIN code: 1886741

-Ends-

Enquiries

Hikma Pharmaceuticals PLC
Susan Ringdal, VP Corporate Strategy and Investor Relations	[phone]/ [phone]
Virginia Spring, Investor Relations Manager	[phone]/ [phone]
FTI Consulting
Ben Atwell/Brett Pollard	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a pharmaceutical group focused on developing, manufacturing and

marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's

operations are conducted through three businesses: 'Branded', 'Injectables' and 'Generics' based

primarily in the Middle East and North Africa (MENA), the United States and Europe.

 

END

 

 

NORMMGZZZNLGRZM